
    
      Each subject will qualify for entry into the study not more than 30 days prior to admission
      into the clinical unit. Subjects will check into the clinical unit on Day -1 for baseline
      assessments. During the treatment period, each subject will receive a once-daily dose of
      pitavastatin 4 mg on Days 1 through 5 and on Days 11 through 15 and a once-daily dose of
      diltiazem 240 mg on Days 6 through 15. Subjects will fast overnight for at least 8 hours
      before dosing and will remain fasted until 4 hours after dosing on the morning of Days 5, 10,
      and 15.
    
  